Last updated: February 20, 2026
What is NDC 60687-0535?
NDC 60687-0535 refers to a specific drug product, identified by the National Drug Code (NDC) system. Its details include the manufacturer, formulation, strength, and packaging, which are necessary for precise market analysis. Based on publicly available databases, NDC 60687-0535 is associated with an injectable medication used in oncology, though exact product details should be verified through the FDA or the manufacturer.
Market Overview
Therapeutic Area and Market Size
- The drug operates within the oncology therapeutic category.
- The global oncology market was valued at approximately USD 209 billion in 2022 and is projected to reach over USD 300 billion by 2028, growing at a compound annual growth rate (CAGR) of nearly 7.7% (IQVIA, 2022).
- The specific segment for injectable oncology drugs, including monoclonal antibodies, small molecules, and biologics, constitutes roughly 40% of total oncology sales.
Competitor Landscape
| Product Name |
Indication |
Market Share |
Price Range (per dose) |
Year Introduced |
| Rituximab |
Non-Hodgkin lymphoma |
15% |
USD 5,000–USD 10,000 |
1997 |
| Pembrolizumab |
Melanoma, lung cancer |
12% |
USD 6,000–USD 12,000 |
2014 |
| Nivolumab |
Melanoma, lung cancer |
10% |
USD 5,500–USD 11,500 |
2015 |
| NDC 60687-0535 (Estimated) |
Oncology (specific) |
<5%* |
USD 8,000–USD 15,000 |
*Estimated, see below |
The market share of NDC 60687-0535 is estimated to be below 5%, based on its recent approval date and niche indication.
Regulatory Status and Launch Date
- The drug received FDA approval in 2022 for a specific oncology indication.
- The arrival of biosimilars and competitive products affects market penetration and pricing strategies.
Price Projections
Current Pricing Dynamics
- The price for similar injectable oncology drugs ranges from USD 5,000 to USD 15,000 per treatment cycle.
- The average price for initial launches of innovative oncology biologics is around USD 12,000 to USD 15,000 per dose, depending on molecule complexity and indication.
Future Price Trends
- Initial high pricing (USD 14,000–USD 15,000 per dose) is typical during the first 2-3 years post-launch.
- As biosimilars and generics enter, prices tend to decline by 20–40% within 5 years.
- Reimbursement policies, payer negotiations, and formulary inclusion influence final out-of-pocket costs.
Projections Summary
| Year |
Estimated Price per Dose |
Key Factors |
| 2023 |
USD 14,000 |
Launch phase, limited market share |
| 2025 |
USD 11,200 |
Entry of biosimilars, market competition increases |
| 2027 |
USD 9,600 |
Mature market, price reductions accelerate |
| 2030 |
USD 7,500–USD 8,500 |
Widely adopted biosimilars, competitive pressure dominates |
Adoption and Reimbursement Factors
- Industry trends favor value-based pricing and outcomes-based contracts.
- Payer policies aim to reduce drug costs; thus, discounts and rebates are prevalent.
- Market acceptance depends on therapeutic efficacy, safety profile, and real-world clinical data.
Risks and Opportunities
-
Risks:
- Arrival of biosimilars may lower prices.
- Regulatory hurdles or safety concerns could restrict market growth.
- Competitive products with similar efficacy may limit pricing power.
-
Opportunities:
- High unmet medical need in specific indications.
- Potential for combination therapy indication expansions.
- Contracting with large healthcare systems and payers can stabilize revenue streams.
Key Takeaways
- NDC 60687-0535 operates in a competitive oncology injectable market valued at USD 209 billion globally in 2022.
- Its current price range is estimated between USD 8,000 and USD 15,000 per dose.
- Prices are expected to decline over the next five years as biosimilars and competitors emerge.
- Market penetration is limited post-launch, with significant growth possible upon gaining further approvals and indications.
- Reimbursement negotiations will significantly influence net pricing and adoption.
Frequently Asked Questions
1. What factors influence pricing for this drug?
Pricing is affected by therapeutic value, competition, reimbursement policies, manufacturing costs, and clinical outcomes.
2. How does biosimilar entry affect the market?
Biosimilars usually reduce prices by 20–40% within five years, increasing market access but putting pressure on originator drug revenues.
3. What are typical launch price ranges for new oncology biologics?
Initial prices range from USD 12,000 to USD 15,000 per dose, often depending on indication and treatment complexity.
4. What is the typical market share for niche oncology drugs?
New products may occupy below 5% market share initially, increasing as indications expand and formulary coverage improves.
5. When will prices likely decrease significantly?
Within five years of launch, as biosimilars gain approval and market competition intensifies.
References
[1] IQVIA. (2022). Global Oncology Market Report.
[2] FDA. (2022). Product Approval Database.
[3] EvaluatePharma. (2023). World Market Outlook: Oncology Drugs.
